These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 31930323)

  • 1. Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia.
    Amarnani R; Travis S; Javaid MK
    Rheumatology (Oxford); 2020 Aug; 59(8):2166-2168. PubMed ID: 31930323
    [No Abstract]   [Full Text] [Related]  

  • 2. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hypophosphatemia, a poorly known adverse reaction of intravenous use of iron].
    Barea Mendoza JA; Gredilla Zubiría I; González Olmedo J; Mateo Alvarez S
    Med Clin (Barc); 2014 Sep; 143(6):284-5. PubMed ID: 24461741
    [No Abstract]   [Full Text] [Related]  

  • 4. Uncommon adverse effect of a common medication.
    Moore KL; Kildahl-Andersen O; Kildahl-Andersen R; Tjønnfjord GE
    Tidsskr Nor Laegeforen; 2013 Jan; 133(2):165. PubMed ID: 23344600
    [No Abstract]   [Full Text] [Related]  

  • 5. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women.
    Wolf M; Koch TA; Bregman DB
    J Bone Miner Res; 2013 Aug; 28(8):1793-803. PubMed ID: 23505057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 8. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy.
    Sangrós Sahún MJ; Goñi Gironés E; Camarero Salazar A; Estébanez Estébanez C; Lozano Martínez ME
    Rev Esp Med Nucl Imagen Mol; 2016; 35(6):391-393. PubMed ID: 27246291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 23-related osteomalacia caused by the prolonged administration of saccharated ferric oxide.
    Yamamoto S; Okada Y; Mori H; Fukumoto S; Tanaka Y
    Intern Med; 2012; 51(17):2375-8. PubMed ID: 22975552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia.
    Schouten BJ; Doogue MP; Soule SG; Hunt PJ
    Ann Clin Biochem; 2009 Mar; 46(Pt 2):167-9. PubMed ID: 19151167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Intravenous ferric carboxymaltose-associated hypophosphatemia in patients with iron deficiency anemia. A common side effect].
    Sánchez González R; Ternavasio-de la Vega HG; Moralejo Alonso L; Inés Revuelta S; Fuertes Martín A
    Med Clin (Barc); 2015 Aug; 145(3):108-11. PubMed ID: 25579771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Kirk SE; Scheurer ME; Bernhardt MB; Mahoney DH; Powers JM
    Am J Hematol; 2021 Jun; 96(6):E215-E218. PubMed ID: 33735470
    [No Abstract]   [Full Text] [Related]  

  • 14. Hypophosphatemic osteomalacia, a side effect of iron carboxymaltose administration.
    Madero Velázquez L; Muñoz Pérez R; Rodríguez A; Bernal L; Orts B; Sempere L; Gutiérrez Casbas A
    Rev Esp Enferm Dig; 2022 Jun; 114(6):358. PubMed ID: 35105150
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ferric carboxymaltose (Injectafer) for iron deficiency anemia.
    Med Lett Drugs Ther; 2013 Dec; 55(1431):99-100. PubMed ID: 24322665
    [No Abstract]   [Full Text] [Related]  

  • 17. [Case report; A case of FGF23-related hypophosphatemic osteomalacia caused by long-term administration of saccharated ferric oxide].
    Wada Y; Kinoshita Y; Taguchi M; Fukumoto S; Fujita T
    Nihon Naika Gakkai Zasshi; 2011 Oct; 100(10):3031-3. PubMed ID: 22175146
    [No Abstract]   [Full Text] [Related]  

  • 18. Sharp rises in FGF23 and hypophosphatemia after intravenous iron administration do not cause myocardial damage.
    Brandenburg V; Heine GH; Marx N; Stöhr R
    Clin Res Cardiol; 2020 Oct; 109(10):1316-1318. PubMed ID: 32215701
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypophosphatemia in children treated with ferric carboxymaltose.
    Posod A; Schaefer B; Mueller T; Zoller H; Kiechl-Kohlendorfer U
    Acta Paediatr; 2020 Jul; 109(7):1491-1492. PubMed ID: 31955454
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized evaluation of efficacy and safety of ferric carboxymaltose in patients with iron deficiency anaemia and impaired renal function (REPAIR-IDA): rationale and study design.
    Szczech LA; Bregman DB; Harrington RA; Morris D; Butcher A; Koch TA; Goodnough LT; Wolf M; Onken JE
    Nephrol Dial Transplant; 2010 Jul; 25(7):2368-75. PubMed ID: 20466657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.